Annual Cash & Cash Equivalents
$19.20 M
-$32.22 M-62.66%
December 31, 2023
Summary
- As of February 7, 2025, JANX annual cash & cash equivalents is $19.20 million, with the most recent change of -$32.22 million (-62.66%) on December 31, 2023.
- During the last 3 years, JANX annual cash & cash equivalents has risen by +$11.39 million (+145.81%).
- JANX annual cash & cash equivalents is now -62.66% below its all-time high of $51.43 million, reached on December 31, 2022.
Performance
JANX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$26.75 M
+$12.09 M+82.47%
September 30, 2024
Summary
- As of February 7, 2025, JANX quarterly cash and cash equivalents is $26.75 million, with the most recent change of +$12.09 million (+82.47%) on September 30, 2024.
- Over the past year, JANX quarterly cash and cash equivalents has increased by +$9.60 million (+55.98%).
- JANX quarterly cash and cash equivalents is now -89.37% below its all-time high of $251.63 million, reached on June 30, 2021.
Performance
JANX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
JANX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -62.7% | +56.0% |
| 3 y3 years | +145.8% | -32.1% |
| 5 y5 years | +2818.7% | - |
JANX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -62.7% | at low | -87.4% | +82.5% |
| 5 y | 5-year | -62.7% | +2818.7% | -89.4% | +242.4% |
| alltime | all time | -62.7% | +2818.7% | -89.4% | +242.4% |
Janux Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $26.75 M(+82.5%) |
| Jun 2024 | - | $14.66 M(-93.1%) |
| Mar 2024 | - | $212.80 M(+1008.1%) |
| Dec 2023 | $19.20 M(-62.7%) | $19.20 M(+12.0%) |
| Sep 2023 | - | $17.15 M(-49.1%) |
| Jun 2023 | - | $33.70 M(+11.0%) |
| Mar 2023 | - | $30.36 M(-41.0%) |
| Dec 2022 | $51.43 M | $51.43 M(-20.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $64.75 M(+10.9%) |
| Jun 2022 | - | $58.40 M(+5.9%) |
| Mar 2022 | - | $55.13 M(+54.9%) |
| Dec 2021 | $35.58 M(+355.4%) | $35.58 M(-9.7%) |
| Sep 2021 | - | $39.39 M(-84.3%) |
| Jun 2021 | - | $251.63 M(+255.6%) |
| Mar 2021 | - | $70.77 M(+805.8%) |
| Dec 2020 | $7.81 M(+1087.4%) | $7.81 M |
| Dec 2019 | $658.00 K | - |
FAQ
- What is Janux Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Janux Therapeutics?
- What is Janux Therapeutics annual cash & cash equivalents year-on-year change?
- What is Janux Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Janux Therapeutics?
- What is Janux Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Janux Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of JANX is $19.20 M
What is the all time high annual cash & cash equivalents for Janux Therapeutics?
Janux Therapeutics all-time high annual cash & cash equivalents is $51.43 M
What is Janux Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, JANX annual cash & cash equivalents has changed by -$32.22 M (-62.66%)
What is Janux Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of JANX is $26.75 M
What is the all time high quarterly cash and cash equivalents for Janux Therapeutics?
Janux Therapeutics all-time high quarterly cash and cash equivalents is $251.63 M
What is Janux Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, JANX quarterly cash and cash equivalents has changed by +$9.60 M (+55.98%)